Clinical Trial Update: A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial (cAMeLot-1) is evaluating Bleximenib in participants with acute leukemia. The study is currently in recruitment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia

Drugs mentioned

• Bleximenib (Bleximenib)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Acute Leukemia | Phase 1, Phase 2 | Status: RECRUITING